Aromatase Inhibitors and Risk of Metabolic and Cardiovascular Adverse Effects in Breast Cancer Patients—A Systematic Review and Meta-Analysis

The Influence of Hormone Therapy on secondary diabetes mellitus in Breast Cancer: A Meta-analysis

(2021) Feng Ye et al.   Clinical Breast Cancer

Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study

(2021) Maria Sund et al.   BREAST

Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer

(2020) Farzin Khosrow-Khavar et al.   CIRCULATION

Menopause-Associated Lipid Metabolic Disorders and Foods Beneficial for Postmenopausal Women

(2020) Seong-Hee Ko et al.   Nutrients

The impact of xenoestrogens on effectiveness of treatment for hormone-dependent breast cancer – current state of knowledge and perspectives for research

(2020) Kamila Boszkiewicz et al.   ANNALS OF AGRICULTURAL AND ENVIRONMENTAL MEDICINE

Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects

(2020) Sara Tenti et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study

(2020) Emily Heer et al.   Lancet Global Health

Exposure to Endocrine Disrupting Chemicals and Risk of Breast Cancer

(2020) Louisane Eve et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Higher Insulin Resistance & Adiposity in Post-menopausal Women With Breast Cancer Treated With Aromatase Inhibitors

(2019) Fraser W Gibb et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Breast Cancer Treatment

(2019) Adrienne G. Waks et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Weight trajectories in women receiving systemic adjuvant therapy for breast cancer

(2019) Kirsten A. Nyrop et al.   BREAST CANCER RESEARCH AND TREATMENT

Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis

(2019) Yang He et al.   BMC Pharmacology & Toxicology

Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study

(2018) Rola Hamood et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

(2018) Sabino De Placido et al.   LANCET ONCOLOGY

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study

(2018) Fabienne Schochter et al.   Oncology Research and Treatment

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

(2018) Eleftherios P Mamounas et al.   LANCET ONCOLOGY

Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial

(2017) Ian Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiotoxicity of Aromatase Inhibitors and Tamoxifen in Post-Menopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

(2016) F. Khosrow-Khavar et al.   ANNALS OF ONCOLOGY

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial

(2016) N. Zdenkowski et al.   ANNALS OF ONCOLOGY

A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer

(2013) Hiroji Iwata et al.   BREAST CANCER RESEARCH AND TREATMENT

Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial

(2013) Paul E. Goss et al.   JOURNAL OF CLINICAL ONCOLOGY

Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04)

(2012) Hiroyuki Takei et al.   BREAST CANCER RESEARCH AND TREATMENT

Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer

(2012) Ivana Sestak et al.   BREAST CANCER RESEARCH AND TREATMENT

Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen

(2011) Yasuhiro Fujiwara et al.   CANCER SCIENCE

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

(2011) Cornelis JH van de Velde et al.   LANCET

Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study

(2010) Tomohiko Aihara et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

(2008) Robert J. Paridaens et al.   JOURNAL OF CLINICAL ONCOLOGY